BIT:1MRKX • US58933Y1055
The current stock price of 1MRKX.MI is 103.2 EUR. Today 1MRKX.MI is up by 14.41%. In the past month the price increased by 49.35%.
ChartMill assigns a technical rating of 6 / 10 to 1MRKX.MI.
ChartMill assigns a fundamental rating of 6 / 10 to 1MRKX.MI. 1MRKX.MI has an excellent profitability rating, but there are some minor concerns on its financial health.
On February 3, 2026 1MRKX.MI reported an EPS of 2.09 and a revenue of 16.40B. The company beat EPS expectations (2.98% surprise) and beat revenue expectations (0.31% surprise).
34 analysts have analysed 1MRKX.MI and the average price target is 99.7 EUR. This implies a price decrease of -3.39% is expected in the next year compared to the current price of 103.2.
For the next year, analysts expect an EPS growth of -41.06% and a revenue growth 4.34% for 1MRKX.MI
Over the last trailing twelve months 1MRKX.MI reported a non-GAAP Earnings per Share(EPS) of 7.74. The EPS increased by 20.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 29.63% | ||
| ROA | 14.69% | ||
| ROE | 36.71% | ||
| Debt/Equity | 0.77 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SAN | SANOFI | 9.04 | 187.74B | ||
| SNW | SANOFI | 9.04 | 187.692B | ||
| 1SAN | SANOFI | 9.02 | 187.378B | ||
| UNC | UCB SA | 24.38 | 51.176B | ||
| UCB | UCB SA | 24.41 | 50.164B | ||
| MRK | MERCK KGAA | 12.81 | 49.217B | ||
| BAYN | BAYER AG-REG | 7.45 | 37.111B | ||
| 1BAYN | BAYER AG-REG | 7.65 | 36.973B | ||
| IPN | IPSEN | 14.11 | 13.795B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 10.059B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.15 | 9.95B | ||
| VIRP | VIRBAC SA | 16.3 | 2.907B | ||
| DMP | DERMAPHARM HOLDING SE | 15.26 | 2.062B |
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey and currently employs 75,000 full-time employees. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
MERCK & CO. INC.
126 East Lincoln Avenue, P.O. Box 2000
Rahway NEW JERSEY US
Employees: 75000
Phone: 19087404000
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey and currently employs 75,000 full-time employees. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
The current stock price of 1MRKX.MI is 103.2 EUR. The price increased by 14.41% in the last trading session.
MERCK & CO. INC. (1MRKX.MI) has a dividend yield of 2.85%. The yearly dividend amount is currently 2.61.
1MRKX.MI has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
34 analysts have analysed 1MRKX.MI and the average price target is 99.7 EUR. This implies a price decrease of -3.39% is expected in the next year compared to the current price of 103.2.
MERCK & CO. INC. (1MRKX.MI) has a market capitalization of 256.14B EUR. This makes 1MRKX.MI a Mega Cap stock.